Brochure
5 Jan 2024

C&EN Issue: A New Dawn for Small-Molecule Drugs

PDF 9.7 MB
Download

With medicinal chemists’ innovative tools and techniques, it’s an exciting time to be building new drugs.

IN BRIEF
At one stage, small-molecule drugs seemed at risk of going out of fashion, as industry began to favor biotherapeutics. But over the past 10 years, small molecules have made it clear that they aren’t going away. New classes of molecules, such as proteolysis-targeting chimeras (PROTACs) and molecular glues, have people excited. So do technologies, such as machine learning and generative artificial intelligence, that are helping drive drug discovery. Today, drug hunters have more ambition to go after difficult targets and to use novel chemistry. And that makes it an exciting time for chemists.

Content provided by our supplier

American Chemical Society (C&EN)

  • US
  • 2016
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Association/Government
Press/Media
View company profile

Other Content from American Chemical Society (C&EN) (2)

  • C&EN 10 Start-Ups to Watch announced for 2023

    News C&EN 10 Start-Ups to Watch announced for 2023

    Chemical & Engineering News announces 2023 list of 10 chemistry start-ups to watch
    5 Jan 2024
  • C&EN Year in Pharma 2023

    Brochure C&EN Year in Pharma 2023

    After several years of disruption and hard work, the pharmaceutical industry has dusted itself off and gotten back to business as usual. The number of drugs approved by the US Food and Drug Administration was certainly back up after 2022’s lean year, and drug companies with bulging coffers went on some high-profile spending sprees, snapping up biotechs to help their business development strategy as patent expirations loom.But what is business as usual? Our post-COVID-19 normality has changed our lives. In 2023, the pandemic-fueled pharma funding bubble also well and truly burst. Beyond the failure of Silicon Valley Bank and rising interest rates, investor sentiment seems to have cooled on biotechnology as a brand. Patients and industry executives are also watching to see how government-mandated price controls may begin affecting the pharma business.Both smaller biotechs and larger firms, such as Pfizer, Bayer, and GSK, ha...